We continue our series of posts which are inspired by Drug Hunter’s “Molecules of the Month” (drughunter.com)!
A molecule that was recently highlighted by Drug Hunter is FLX475 - an oral CCR4 antagonist in Phase II trials for immuno-oncology, discovered through optimization of prior CCR4 ligands.
FLX475 is designed to block the recruitment of immunosuppressive regulatory T cells (Treg) into tumors without affecting healthy tissues. By blocking Treg migration into the tumor environment, FLX475 has the potential to boost the body's natural antitumor immunity.
You can find the analogs to this molecule by this link!
Use chem-space.com/search to find off-the-shelf and Make-on-Demand molecules of your interest!
